Comparative analysis of efficacy between autoimplantation and intralesional MMR vaccine in viral warts

Comparative analysis of efficacy between homologous autoimplantation therapy and intralesional MMR vaccine in the treatment of viral warts. - MAVW

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/062715

Enrollment

Registered

2024-02-15

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Intralesional Injection MMR: 0.5 ml Injection MMR injected in each cutaneous wart at a interval of 3 weeks upto 5 sittings Control Intervention1: Homologous autoimplantation: Full thick

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients more than 12 years of age with multiple warts less than 10 in number who are willing to participate in the study

Exclusion criteria

Exclusion criteria: 1)Single wart 2)Pregnant or planning pregnancy in the next three months 3)Lactating women 4)Patients with local dermatological condition 5)Patients with apparent infection, immunosuppression, or are on immunosuppressive drugs, asthma, allergic skin disorders, meningitis or convulsions

Design outcomes

Primary

Measure	Time frame
Reduction in size of wart assessed by VAS scoring systemTimepoint: Baseline,3 weeks, 6 weeks, 9 weeks, 12 weeks	—

Secondary

Measure	Time frame
To assess adverse reactions in Inralesional Injection MMR & AutoimplantationTimepoint: Baseline, 3 weeks, 6 weeks, 9 weeks, 12 weeks	—

Countries

India

Contacts

Public ContactAditi P Shete

Jawaharlal Nehru Medical College, Belagavi

sharada24101992@gmail.com8971670453

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026